595 related articles for article (PubMed ID: 17302253)
1. One-year entecavir or lamivudine therapy results in reduction of hepatitis B virus intrahepatic covalently closed circular DNA levels.
Wong DK; Yuen MF; Ngai VW; Fung J; Lai CL
Antivir Ther; 2006; 11(7):909-16. PubMed ID: 17302253
[TBL] [Abstract][Full Text] [Related]
2. Quantitative analysis of HBV cccDNA from clinical specimens: correlation with clinical and virological response during antiviral therapy.
Bourne EJ; Dienstag JL; Lopez VA; Sander TJ; Longlet JM; Hall JG; Kwiatkowski RW; Wright T; Lai CL; Condreay LD
J Viral Hepat; 2007 Jan; 14(1):55-63. PubMed ID: 17212645
[TBL] [Abstract][Full Text] [Related]
3. Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection.
Lai CL; Rosmawati M; Lao J; Van Vlierberghe H; Anderson FH; Thomas N; Dehertogh D
Gastroenterology; 2002 Dec; 123(6):1831-8. PubMed ID: 12454840
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of entecavir in lamivudine-refractory patients with chronic hepatitis B: randomized controlled trial in Japanese patients.
Suzuki F; Toyoda J; Katano Y; Sata M; Moriyama M; Imazeki F; Kage M; Seriu T; Omata M; Kumada H
J Gastroenterol Hepatol; 2008 Sep; 23(9):1320-6. PubMed ID: 18554238
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of entecavir for chronic HBV in HIV/HBV coinfected patients receiving lamivudine as part of antiretroviral therapy.
Pessôa MG; Gazzard B; Huang AK; Brandão-Mello CE; Cassetti I; Mendes-Corrêa MC; Soriano V; Phiri P; Hall A; Brett-Smith H
AIDS; 2008 Sep; 22(14):1779-87. PubMed ID: 18753861
[TBL] [Abstract][Full Text] [Related]
6. Effect of lamivudine therapy on the serum covalently closed-circular (ccc) DNA of chronic hepatitis B infection.
Yuen MF; Wong DK; Sum SS; Yuan HJ; Yuen JC; Chan AO; Wong BC; Lai CL
Am J Gastroenterol; 2005 May; 100(5):1099-103. PubMed ID: 15842584
[TBL] [Abstract][Full Text] [Related]
7. A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patients.
Chang TT; Gish RG; Hadziyannis SJ; Cianciara J; Rizzetto M; Schiff ER; Pastore G; Bacon BR; Poynard T; Joshi S; Klesczewski KS; Thiry A; Rose RE; Colonno RJ; Hindes RG;
Gastroenterology; 2005 Oct; 129(4):1198-209. PubMed ID: 16230074
[TBL] [Abstract][Full Text] [Related]
8. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.
Chang TT; Gish RG; de Man R; Gadano A; Sollano J; Chao YC; Lok AS; Han KH; Goodman Z; Zhu J; Cross A; DeHertogh D; Wilber R; Colonno R; Apelian D;
N Engl J Med; 2006 Mar; 354(10):1001-10. PubMed ID: 16525137
[TBL] [Abstract][Full Text] [Related]
9. Entecavir for the treatment of chronic hepatitis B virus infection.
Matthews SJ
Clin Ther; 2006 Feb; 28(2):184-203. PubMed ID: 16678641
[TBL] [Abstract][Full Text] [Related]
10. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.
Lai CL; Shouval D; Lok AS; Chang TT; Cheinquer H; Goodman Z; DeHertogh D; Wilber R; Zink RC; Cross A; Colonno R; Fernandes L;
N Engl J Med; 2006 Mar; 354(10):1011-20. PubMed ID: 16525138
[TBL] [Abstract][Full Text] [Related]
11. Covalently closed-circular hepatitis B virus DNA reduction with entecavir or lamivudine.
Bowden S; Locarnini S; Chang TT; Chao YC; Han KH; Gish RG; de Man RA; Yu M; Llamoso C; Tang H
World J Gastroenterol; 2015 Apr; 21(15):4644-51. PubMed ID: 25914474
[TBL] [Abstract][Full Text] [Related]
12. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B.
Gish RG; Lok AS; Chang TT; de Man RA; Gadano A; Sollano J; Han KH; Chao YC; Lee SD; Harris M; Yang J; Colonno R; Brett-Smith H
Gastroenterology; 2007 Nov; 133(5):1437-44. PubMed ID: 17983800
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of entecavir treatment for lamivudine-resistant hepatitis B over 3 years: histological improvement or entecavir resistance?
Suzuki Y; Suzuki F; Kawamura Y; Yatsuji H; Sezaki H; Hosaka T; Akuta N; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Miyakawa Y; Kumada H
J Gastroenterol Hepatol; 2009 Mar; 24(3):429-35. PubMed ID: 19226381
[TBL] [Abstract][Full Text] [Related]
14. Association of intrahepatic cccDNA reduction with the improvement of liver histology in chronic hepatitis B patients receiving oral antiviral agents.
Cheng PN; Liu WC; Tsai HW; Wu IC; Chang TT; Young KC
J Med Virol; 2011 Apr; 83(4):602-7. PubMed ID: 21328373
[TBL] [Abstract][Full Text] [Related]
15. Selection of an entecavir-resistant mutant despite prolonged hepatitis B virus DNA suppression, in a chronic hepatitis B patient with preexistent lamivudine resistance: successful rescue therapy with tenofovir.
Leemans WF; Niesters HG; van der Eijk AA; Janssen HL; Schalm SW; de Man RA
Eur J Gastroenterol Hepatol; 2008 Aug; 20(8):773-7. PubMed ID: 18617782
[TBL] [Abstract][Full Text] [Related]
16. Effects of entecavir on hepatitis B virus covalently closed circular DNA in hepatitis B e antigen-positive patients with hepatitis B.
Shi M; Sun WL; Hua YY; Han B; Shi L
PLoS One; 2015; 10(2):e0117741. PubMed ID: 25647607
[TBL] [Abstract][Full Text] [Related]
17. [Effects of antiviral agents on intrahepatic ccc DNA in HBeAg-positive chronic hepatitis B patients].
Lu HY; Zhuang LW; Yu YY; Si CW; Li J
Zhonghua Gan Zang Bing Za Zhi; 2008 Mar; 16(3):198-202. PubMed ID: 18364079
[TBL] [Abstract][Full Text] [Related]
18. Quantitation of covalently closed circular hepatitis B virus DNA in chronic hepatitis B patients.
Wong DK; Yuen MF; Yuan H; Sum SS; Hui CK; Hall J; Lai CL
Hepatology; 2004 Sep; 40(3):727-37. PubMed ID: 15349913
[TBL] [Abstract][Full Text] [Related]
19. Relapse of hepatitis B in HBeAg-negative chronic hepatitis B patients who discontinued successful entecavir treatment: the case for continuous antiviral therapy.
Shouval D; Lai CL; Chang TT; Cheinquer H; Martin P; Carosi G; Han S; Kaymakoglu S; Tamez R; Yang J; Tenney D; Brett-Smith H
J Hepatol; 2009 Feb; 50(2):289-95. PubMed ID: 19070393
[TBL] [Abstract][Full Text] [Related]
20. Intracellular levels of hepatitis B virus DNA and pregenomic RNA in peripheral blood mononuclear cells of chronically infected patients.
Lu L; Zhang HY; Yueng YH; Cheung KF; Luk JM; Wang FS; Lau GK
J Viral Hepat; 2009 Feb; 16(2):104-12. PubMed ID: 19175882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
